Shanghai Bio Road Gene Development, Ltd.

Integrated Device Technology, Inc.

Shanghai Bio Window Gene Development, Inc.

Hengsun Pharmaceutical Technology Co. Ltd.

Biowindow Gene Development Inc.

Yi Xie

Yumin Mao

Yue Yu

Yuan Yuan Zhang

HaiQi Liu

Yu Zhang

Jian Wang

Yumin Zhang

Chaoneng Ji

Wanxiang Xu

Haiping Tang

Zhida Sun

Shaohua Gu

Yaping He

An apparatus includes an interface and a plurality of impedance branches. The interface may be configured to receive a data signal and a plurality of selection signals. The plurality of impedance branches may comprise a group of branches and a separated branch. The plurality of impedance branches may be configured to adjust an impedance value and a gain of a data path for the data signal in response to the selection signals. The group of branches may be controlled in response to the selection signals to select the impedance value and a first gain value in a first mode. The separated branch may replace one of the plurality of impedance branches in the group of branches in response to the selection signals to select a second gain value in a second mode.

Wide programmable gain receiver data path for single-ended memory interface application

An apparatus includes a line-termination circuit and a continuous-time linear equalizer circuit. The line-termination circuit may be configured to generate a data signal in response to an input signal. The input signal generally resides in a first voltage domain. The input signal may be single-ended. The data signal may be generated in the first voltage domain. The continuous-time linear equalizer circuit may be configured to generate an intermediate signal by equalizing the data signal relative to a reference voltage. The continuous-time linear equalizer circuit generally operates in a second voltage domain. The first voltage domain may be higher than the second voltage domain.

High signal voltage tolerance in single-ended memory interface

An apparatus having a first circuit and a second circuit. The first circuit may be configured to buffer an input signal received as a single-ended signal from a data bus connected between a memory channel and a memory controller. The second circuit may be configured to condition the input signal relative to a reference voltage to generate a differential signal. The reference voltage may be isolated from the second circuit in response to a transition from a power down condition to a power on condition.

Single-ended memory signal equalization at power up

An apparatus includes a first circuit, a second circuit, and a third circuit. The first circuit may be configured to (i) reduce a current value in a sequence of input values that have been carried on a single-ended line of a data bus coupled to a memory channel to generate a version of the current value, and (ii) reduce a first reference voltage to generate a second reference voltage. The second circuit may be configured to slice the current value with respect to the first reference voltage to generate a first intermediate value. The third circuit may be configured to slice the version of the current value with respect to the second reference voltage to generate a second intermediate value. The first intermediate value and the second intermediate value generally define a sliced value of the current value.

Single-ended signal slicer with a wide input voltage range

An apparatus includes a first circuit and a second circuit. The first circuit may be configured to (i) receive a sequence of input values that have been carried on a single-ended line of a data bus coupled to a memory channel, (ii) slice a previous input value of said sequence of input values to generate a previous output value, (iii) slice a current input value of said sequence of input values to generate a current output value, and (iv) present said current output value on a differential line. The previous input value generally precedes said current input value in said sequence of input values. The second circuit may be configured to decode said previous input value based on a tap coefficient value to generate a plurality of feedback values suitable to reduce an inter-symbol interference in said current input value caused by said previous input value.

Single-ended signal equalization with a programmable 1-tap decision feedback equalizer

Minimal Motifs of linear B-cell epitopes in L1 structure protein from human papillomavirus type 58 (HPV 58) and their applications are disclosed. Eighteen linear epitope motifs and their extended 8-mer peptides in the L1 protein from HPV 58 are described, which can be used as antigens separately or in combination to specifically detect the serum from subjects with HPV 58 infection, or to develop preventive or therapeutic multi-epitope peptide vaccines against HPV 58 by inducing humoral immunity. Of the eighteen B-cell epitope motifs, ten of them are 100% conservative and one is highly conservative among many homologous proteins of high-risk HPVs. They can be used as candidate 'universal' epitopes to develop preventive or therapeutic HPV vaccines. The amino acid sequences of the epitope motifs and the 8-mer peptide formula of the invention are shown below in SEQ ID No. 1-2, 2B, 3, 3B, 4-18, 18B, 19, 19B, and 20-32.

Minimal motifs of linear B-cell epitopes in L1 protein from human papillomavirus type 58 and their applications

The present invention discloses a novel polypeptide&#x2014;human actin-binding protein 54 and a polynucleotide encoding the same, as well as a method of producing the polypeptide by DNA recombinant technology. The present invention also discloses methods of using the polypeptide in treatment of various diseases, such as malignant tumor, blood disease, HIV infection, immunological diseases and various inflammation. The present invention also discloses an antagonist against the polypeptide and the therapeutic use of the same. The present invention also discloses the use of such polynucleotide encoding human actin-binding protein 54.

Polypeptide-human actin-binding protein 54 and a polynucleotide encoding the same

The invention disclosed a new kind of polypeptide-phosphatidic acid phosphatase 29.81 and the polynucleotide encoding said polypeptide and a process for priducing the polypeptide by DNA recombinant methods. It also disclosed the method of applying the polypeptide for the treatment of various kinds of diseases, such as peripheral nervous demyelination, night blindness, rachitis, fatty liver, bronchial asthma and peptic ulcer. The antagonist of the polypeptide and therapeutic use of the same is also disclosed. In addition, it refers to the use of polynucleotide encoding said phosphatidic acid phosphatase 29.81.

Polypeptide-phosphatidic acid phosphatase 29.81 and the polynucleotide encoding said polypeptide

Novel human polyadenylation binding Protein 20.13 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique, and methods for treating many diseases e.g. disorder of embryo development, growth developmental disturbant diseases etc. The invention also discloses antagonists against the polypeptide.

Polypeptide human polyadenylation binding protein 20.13 and polynucleotide encoding it

The invention discloses a novle human vacuolar H-ATPase C subunit 42 and a polynucleotide encoding it. The invention also concerns a process of producing the polypeptide by recombinant DNA techniques. Methods are also disclosed for treating many diseases, e.g. malignant tumors, hemopathies, HIV infections, immune diseases and inflammations utilizing the ploypeptide. The invention discloses antagonists of the polypeptide and therapeutics comprising the same. The invention also discloses the uses of the polynucleotide, which encodes the human vacuolar H-ATPase C subunit 42.

[object Object]

The present invention discloses a novel polypeptide, a steroid dehydrogenase 34, the polynucleotide encoding the polypeptide and the method for producing the polypetide by DNA recombinant technology. The invention also discloses the uses of the polypeptide in methods for tresting various diseases, such as steroid hormone dysbolismus disease, such as sex dysgenopathy, some endocrine and metabolic syndrome, viarous tumors of human reproductive system, bile acid dysbolismus, etc. The invention also discloses the agonists against the polypeptide and the therapeutic action thereof. The invention also discloses the uses of the polynucleotide encoding the novel steroid dehydrogenase 34.

Steroid dehydrogenase 34 and the polynucleotide encoding same

The present invention discloses a novel polypeptide-human galectin 15 and a polynucleotide encoding the same, as well as a method of producing the polypeptide by DNA recombinant technology. The present invention also discloses methods of using the polypeptide in treatment of various diseases, such as malignant tumor, blood disease, HIV infection, immunological disease and various inflammations. The present invention also discloses an antagonist against the polypeptide and the therapeutic use of the same.

Polypeptide&#x2014;human galectin 15 and a polynucleotide encoding the same

The present invention discloses a novel polypeptide-Human SNARE protein 25 and polynucleotide encoding the same, as well as a method of producing the polypeptide by DNA recombinant technology. The present invention also discloses methods of using the polypeptide in treatment of various diseases, such as malignant tumor, blood disease, HIV infection, immunological disease and various inflammations. The present invention also discloses an antagonist against the polypeptide and the therapeutic use of the same. The present invention also discloses the use of such polynucleotide encoding Human SNARE protein 25.

Polypeptide-human SNARE protein 25 and a polynucleotide encoding the same

The invention discloses a new kind of RNA binding protein 33 and polynucleotide encoding the polypeptide and a process for producing the polypeptide by recombinant methods. It also discloses the method of applying the polypeptide for the treatment of various kinds of diseases, such as cancer, hemopathology, HIV infection, immune diseases and inflammation. The antibody and antagonist of the polypeptide and the therapeutic use of the same is also disclosed. In addition, it refers to the use of polynucleotide encoding said RNA binding protein 33.

Growing community of inventors

Shanghai, China

Yi Xie